ChemSpider 2D Image | entospletinib | C23H21N7O

entospletinib

  • Molecular FormulaC23H21N7O
  • Average mass411.459 Da
  • Monoisotopic mass411.180756 Da
  • ChemSpider ID31042596

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

1229208-44-9 [RN]
6-(1H-Indazol-6-yl)-N-[4-(4-morpholinyl)phenyl]imidazo[1,2-a]pyrazin-8-amin [German] [ACD/IUPAC Name]
6-(1H-Indazol-6-yl)-N-[4-(4-morpholinyl)phenyl]imidazo[1,2-a]pyrazin-8-amine [ACD/IUPAC Name]
6-(1H-Indazol-6-yl)-N-[4-(4-morpholinyl)phényl]imidazo[1,2-a]pyrazin-8-amine [French] [ACD/IUPAC Name]
6-(2H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine
6I3O3W6O3B
entospletinib [INN] [USAN]
entospletinib [Spanish] [INN]
entosplétinib [French] [INN]
entospletinibum [Latin] [INN]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

9874 [DBID]
GS-9973 [DBID]
gs9973 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Bio Activity:

      GS-9973 is a highly selective and orally efficacious Syk inhibitor(IC50= 7.7 nM) which is currently undergoing clinical evaluation for autoimmune and oncology indications. MedChem Express
      GS-9973 is a highly selective and orally efficacious Syk inhibitor(IC50= 7.7 nM) which is currently undergoing clinical evaluation for autoimmune and oncology indications.; IC50 value: 7.7 nM [1]; Target: Syk; The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. MedChem Express HY-15968
      GS-9973 is a highly selective and orally efficacious Syk inhibitor(IC50= 7.7 nM) which is currently undergoing clinical evaluation for autoimmune and oncology indications.;IC50 value: 7.7 nM [1];Target: Syk;The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that GS-9973 is a more selective Syk inhibitor would provide a greater therapeutic window. MedChem Express HY-15968
      Protein Tyrosine Kinase/RTK MedChem Express HY-15968
      Protein Tyrosine Kinase/RTK; MedChem Express HY-15968
      Syk MedChem Express HY-15968

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

Density: 1.5±0.1 g/cm3
Boiling Point:
Vapour Pressure:
Enthalpy of Vaporization:
Flash Point:
Index of Refraction: 1.772
Molar Refractivity: 117.8±0.5 cm3
#H bond acceptors: 8
#H bond donors: 2
#Freely Rotating Bonds: 4
#Rule of 5 Violations: 0
ACD/LogP: 3.74
ACD/LogD (pH 5.5): 2.56
ACD/BCF (pH 5.5): 45.63
ACD/KOC (pH 5.5): 455.75
ACD/LogD (pH 7.4): 2.81
ACD/BCF (pH 7.4): 80.04
ACD/KOC (pH 7.4): 799.51
Polar Surface Area: 83 Å2
Polarizability: 46.7±0.5 10-24cm3
Surface Tension: 63.7±7.0 dyne/cm
Molar Volume: 283.1±7.0 cm3

Click to predict properties on the Chemicalize site


Advertisement